Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 1
1976 1
1978 2
1980 2
1981 1
1982 2
1983 2
1984 2
1985 3
1986 4
1987 2
1988 2
1990 2
1991 1
1993 1
1994 1
1995 1
1999 2
2000 1
2001 1
2002 5
2003 2
2006 1
2009 2
2011 1
2012 2
2013 1
2014 3
2015 2
2016 1
2017 4
2018 6
2019 2
2020 4
2021 4
2022 2
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

78 results

Results by year

Filters applied: . Clear all
Page 1
Treatment of chylomicronemia.
Navarro Hermoso A, Valdivielso P. Navarro Hermoso A, et al. Clin Investig Arterioscler. 2021 May;33 Suppl 2:75-79. doi: 10.1016/j.arteri.2021.01.004. Clin Investig Arterioscler. 2021. PMID: 34006359 English, Spanish.
Fasting chylomicronaemia appears in type V (multifactorial chylomicronaemia syndrome, MCS), and in type I (familial chylomicronaemia syndrome, FCS). MCS needs to be treated as in any general hypertriglyceridaemia: low-calorie diet, avoid sugar and alcohol, reduce bo …
Fasting chylomicronaemia appears in type V (multifactorial chylomicronaemia syndrome, MCS), and in type I (familial chylomicro …
Familial hypercholesterolemia: Review of diagnosis, screening, and treatment.
Turgeon RD, Barry AR, Pearson GJ. Turgeon RD, et al. Can Fam Physician. 2016 Jan;62(1):32-7. Can Fam Physician. 2016. PMID: 26796832 Free PMC article. Review.
A supporting level of evidence for each recommendation was categorized as level I (randomized controlled trial or systematic review of randomized controlled trials), level II (observational study), or level III (expert opinion). The best available evidence is mostly level …
A supporting level of evidence for each recommendation was categorized as level I (randomized controlled trial or systematic review of rando …
Familial hypercholesterolemia: developments in diagnosis and treatment.
Klose G, Laufs U, März W, Windler E. Klose G, et al. Dtsch Arztebl Int. 2014 Aug 4;111(31-32):523-9. doi: 10.3238/arztebl.2014.0523. Dtsch Arztebl Int. 2014. PMID: 25145510 Free PMC article. Review.
Statins, combined with a health-promoting lifestyle, are the treatment of choice. Lipoprotein apheresis is used in very severe cases; its therapeutic effects on clinical endpoints and its side effect profile have not yet been documented in randomized controlled trials. ...
Statins, combined with a health-promoting lifestyle, are the treatment of choice. Lipoprotein apheresis is used in very severe cases; its …
Familial Chylomicronemia Syndrome (FCS): Recent Data on Diagnosis and Treatment.
Gallo A, Béliard S, D'Erasmo L, Bruckert E. Gallo A, et al. Curr Atheroscler Rep. 2020 Aug 27;22(11):63. doi: 10.1007/s11883-020-00885-1. Curr Atheroscler Rep. 2020. PMID: 32852651 Review.
We focused the paper on new diagnostic tools, progress in understanding the role of two key proteins (apolipoprotein CIII (apo CIII) and angiopoietin-like3 (ANGPTL-3)), and new therapeutic options. RECENT FINDINGS: Recently, a new diagnostic tool has been proposed by Europ …
We focused the paper on new diagnostic tools, progress in understanding the role of two key proteins (apolipoprotein CIII (apo CIII) and ang …
Novel treatment options for the management of heterozygous familial hypercholesterolemia.
Polychronopoulos G, Tziomalos K. Polychronopoulos G, et al. Expert Rev Clin Pharmacol. 2017 Dec;10(12):1375-1381. doi: 10.1080/17512433.2017.1378096. Epub 2017 Sep 14. Expert Rev Clin Pharmacol. 2017. PMID: 28884604 Review.
In this selected subgroup of the FH population, proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors provide substantial reductions in LDL-C levels, reduce cardiovascular morbidity and appear to be safe. ...Other LDL-C-lowering agents under evaluation include i …
In this selected subgroup of the FH population, proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors provide substantial …
The brave new world of genetic testing in the management of the dyslipidaemias.
Nawawi HM, Chua YA, Watts GF. Nawawi HM, et al. Curr Opin Cardiol. 2020 May;35(3):226-233. doi: 10.1097/HCO.0000000000000721. Curr Opin Cardiol. 2020. PMID: 32097179 Review.
Hypertriglyceridaemia may be caused by rare recessive monogenic, or by polygenic, gene variants; genetic testing may be useful in the former, for which antisense therapy targeting apoC-III has been approved. Familial high-density lipoprotein deficiency is caused by …
Hypertriglyceridaemia may be caused by rare recessive monogenic, or by polygenic, gene variants; genetic testing may be useful in the former …
Pharmacological treatment options for severe hypertriglyceridemia and familial chylomicronemia syndrome.
Chaudhry R, Viljoen A, Wierzbicki AS. Chaudhry R, et al. Expert Rev Clin Pharmacol. 2018 Jun;11(6):589-598. doi: 10.1080/17512433.2018.1480368. Epub 2018 Jun 11. Expert Rev Clin Pharmacol. 2018. PMID: 29842811 Review.
Previously, a gene therapy approach to LPL-alipogene tiparvovec showed that direct targeting of LPL function reduced pancreatitis events. ...The availability of antisense anti-apoC3 therapies and, in the future, ANGPTL3 therapies may remedy this....
Previously, a gene therapy approach to LPL-alipogene tiparvovec showed that direct targeting of LPL function reduced pancreatitis eve …
78 results